SCHEMBL4983190

SCHEMBL4983190

COc1ccc(-c2cc(=O)c3cc(I)ccc3o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 1.00
MAPT P10636 5/20 0.79
TP53 P04637 5/20 0.79
CYP3A4 P08684 5/20 0.79
KDM4E B2RXH2 4/20 0.79
ALDH1A1 P00352 4/20 0.79
HPGD P15428 4/20 0.79
NPC1 O15118 3/20 0.79
RAB9A P51151 3/20 0.79
HSD17B10 Q99714 3/20 0.79
NFKB1 P19838 2/20 0.79
NFKB2 Q00653 2/20 0.79
RELA Q04206 2/20 0.79
LMNA P02545 2/20 0.79
THRB P10828 2/20 0.79
SMN1; SMN2 Q16637 2/20 0.79
RXFP1 Q9HBX9 1/20 0.79
KCNA5 P22460 3/20 0.73
KCNH2 Q12809 3/20 0.73
MEN1 O00255 4/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
6,4'-Dimethoxyflavone SCHEMBL29478471 0.88 MAPT (1.00) APPMAPTTP53CYP3A4KDM4E
6,4'-Dimethoxyflavone SCHEMBL4281291 0.88 MAPT (1.00) APPMAPTTP53CYP3A4KDM4E
SCHEMBL535143 0.84 KCNA5 (1.00) APPMAPTTP53CYP3A4KDM4E
SCHEMBL31238310 0.84 MAPT (0.91) APPMAPTTP53CYP3A4KDM4E
SCHEMBL13169617 0.83 MAOB (0.80) APPMAPTTP53CYP3A4KDM4E
SCHEMBL490928 0.83 MAPT (1.00) APPMAPTTP53CYP3A4KDM4E
SCHEMBL4990151 0.83 GABRP (1.00) APPMAPTTP53CYP3A4KDM4E
SCHEMBL925773 0.83 MAPT (0.79) APPMAPTTP53CYP3A4KDM4E
SCHEMBL31675989 0.83 MAPT (1.00) APPMAPTTP53CYP3A4KDM4E
SCHEMBL13169589 0.83 GABRP (1.00) APPMAPTTP53CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8192717-B2 Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening NAGASAKI UNIVERSITY (JP) 2012-06-05 US disclosed
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases Mori, Hiroshi (JP) 2008-06-05 US disclosed
EP-1815872-A1 COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS Nagasaki University (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases APP, APBA1, FABP7 APP 1/4885MAPT 20/4885TP53 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.